| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Tao Wei | |
| Wen-Fang Xu | |||
| Mei-Rong Jia | |||
| P2860 | cites work | Methionine enkephalin is hydrolyzed by aminopeptidase N on CD4+ and CD8+ spleen T cells | Q72677960 |
| The effect of peptidase inhibitors on the release of met5-enk-arg6-phe7 (YGGFMRF) and met5-enkephalin (YGGFM) from spinal cord induced by substance P in vivo | Q72723432 | ||
| Peripherally active analgesia of aminopeptidase-resistant sugar-coupled leucine enkephalin | Q73121263 | ||
| Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse | Q73367338 | ||
| Enzymatic inactivation of enkephalin neurotransmitters in the spinal cord of the neonatal rat | Q73544660 | ||
| Sciatic nerve ligation-induced proliferation of spinal cord astrocytes is mediated by kappa opioid activation of p38 mitogen-activated protein kinase | Q24683304 | ||
| Endogenous peptide: Met-enkephalin-Arg-Phe, differently regulate expression of opioid receptors on chronic treatment | Q28256794 | ||
| A novel analgesic dipeptide from bovine brain is a possible Met-enkephalin releaser | Q28271569 | ||
| Endomorphins: novel endogenous mu-opiate receptor agonists in regions of high mu-opiate receptor density | Q33838460 | ||
| Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. | Q33990607 | ||
| Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes | Q34065254 | ||
| Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone | Q34213404 | ||
| A potent and selective endogenous agonist for the mu-opiate receptor | Q34420509 | ||
| Dynorphin A activates bradykinin receptors to maintain neuropathic pain | Q34582923 | ||
| Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. | Q34602588 | ||
| Probable involvement of alpha(2C)-adrenoceptor subtype and endogenous opioid peptides in the peripheral antinociceptive effect induced by xylazine. | Q34950593 | ||
| Metabolism of dynorphin A 1-13 in human blood and plasma. | Q36672007 | ||
| The endomorphin system and its evolving neurophysiological role | Q36747911 | ||
| The structure and main functions of aminopeptidase N. | Q36754546 | ||
| Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function | Q37362389 | ||
| Peptidases that terminate the action of enkephalins. Consideration of physiological importance for amino-, carboxy-, endo-, and pseudoenkephalinase | Q39827886 | ||
| Restoration of impaired immune functions of aged animals by chronic bestatin treatment | Q39902293 | ||
| Identification and characterization of two distinct kyotorphin-hydrolyzing enzymes in rat brain | Q48646304 | ||
| Hydrolytic deactivation of kyotorphin by the rodent brain homogenates and sera. | Q48649020 | ||
| Aminopeptidase P from rat brain. Purification and action on bioactive peptides | Q48719143 | ||
| Peptidase inhibitors potentiate the effects of neurotensin and neuromedin N on self-stimulation of the medial prefrontal cortex. | Q49109612 | ||
| Bestatin, an inhibitor of aminopeptidases, provides a chemical genetics approach to dissect jasmonate signaling in Arabidopsis. | Q51585234 | ||
| Effects of a mixture of peptidase inhibitors (amastatin, captopril and phosphoramidon) on Met-enkephalin-, beta-endorphin-, dynorphin-(1-13)- and electroacupuncture-induced antinociception in rats. | Q51621166 | ||
| Evaluation of a novel aminopeptidase N inhibitor, in vitro, using two assay systems | Q60688376 | ||
| Degradation of Met-enkephalin by hemolymph peptidases in Mytilus edulis | Q67508119 | ||
| The chemical synthesis of bestatin | Q67789267 | ||
| Effects of beta-endorphin and dynorphin A on cholinergic neurotransmission in canine airway smooth muscle | Q68159895 | ||
| Hematopoietic and hematologic properties of bestatin in normal and cyclophosphamide myelosuppressed mice | Q68577896 | ||
| Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults | Q68577898 | ||
| Prevention of degradation of endogenous enkephalins produces inhibition of nociceptive neurones in rat spinal cord | Q68764107 | ||
| Bestatin potentiates the antinociception but not the motor dysfunction induced by intracerebrally administered dynorphin-B in mice | Q69371825 | ||
| New bidentates as full inhibitors of enkephalin-degrading enzymes: synthesis and analgesic properties | Q69905381 | ||
| Effect of inhibition of neuropeptidases on the pain threshold of mice and rats | Q70316400 | ||
| Effect of bestatin and thiorphan on [Met5]enkephalin-Arg6-Phe7-induced analgesia | Q70401976 | ||
| Inhibition of enkephalin metabolism by, and antinociceptive activity of, bestatin, an aminopeptidase inhibitor | Q70898885 | ||
| Central effects of tuftsin | Q70936505 | ||
| Central antinociceptive effect of L-ornithine, a metabolite of L-arginine, in rats and mice | Q71292774 | ||
| Kyotorphin synthetase activity in rat adrenal glands and spinal cord | Q71336137 | ||
| Formation of desTyr dynorphins 5-17 by a purified cytosolic aminopeptidase of rat brain | Q71398087 | ||
| Enkephalin degradation in the guinea-pig ileum: effect of aminopeptidase inhibitors, puromycin and bestatin | Q71655076 | ||
| Enkephalin metabolism by microglial aminopeptidase N (CD13) | Q71680900 | ||
| Tuftsin and D-Arg3-tuftsin possess analgesic action | Q71852707 | ||
| [Antinociceptive effects of counterirritants] | Q72535051 | ||
| Dynorphin: Potent analgesic effect in spinal cord of the rat | Q72544805 | ||
| Hypoalgesic action of bestatin analogues that inhibit central aminopeptidases, but not neutral endopeptidase | Q72624553 | ||
| Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxypeptidase (“enkephalinase”) as neuropeptidase | Q40126762 | ||
| Different Brain Areas Mediate the Analgesic and Epileptic Properties of Enkephalin | Q40137429 | ||
| Dual inhibitors of enkephalin-degrading enzymes (neutral endopeptidase 24.11 and aminopeptidase N) as potential new medications in the management of pain and opioid addiction | Q41065457 | ||
| Intrathecal administration of thiorphan, bestatin, desipramine and fluoxetine differentially potentiate the antinociceptive effects induced by beta-endorphin and morphine, administered intracerebroventricularly | Q41197199 | ||
| Intrathecal administration of thiorphan and bestatin enhances the antinociception and release of Met-enkephalin induced by beta-endorphin intraventricularly in anesthetized rats | Q41212717 | ||
| Involvement of monoaminergic and peptidergic components in cathinone-induced analgesia | Q41504146 | ||
| Involvement of enzymatic degradation in the inactivation of tachykinin neurotransmitters in neonatal rat spinal cord | Q41809899 | ||
| Role of kappa opioid receptors in modulating cholinergic twitches in the circular muscle of guinea-pig colon | Q42249682 | ||
| Activation of protein kinase C antagonizes the opioid inhibition of calcium current in rat spinal dorsal horn neurons | Q42464863 | ||
| Degradation kinetics of leucine5-enkephalin by plasma samples from healthy controls and various patient populations: in vitro drug effects | Q43585183 | ||
| Effects of intracerebroventricularly administered chimeric peptide of metenkephalin and FMRFa--[D-Ala2]YFa-on antinociception and its modulation in mice | Q43654296 | ||
| Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse | Q43745077 | ||
| Analgesic effect of endomorphin-1. | Q43827872 | ||
| The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids | Q43845201 | ||
| Neutral endopeptidase knockout induces hyperalgesia in a model of visceral pain, an effect related to bradykinin and nitric oxide | Q43946088 | ||
| Effects of naloxone and post-tetanic stimulation on isolated guinea-pig ileum followed by long exposure to morphine and bestatin | Q44142082 | ||
| [Met5]enkephalin-Arg-Gly-Leu-induced antinociception is greatly increased by peptidase inhibitors | Q44189178 | ||
| Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase | Q44332993 | ||
| Receptor binding properties and antinociceptive effects of chimeric peptides consisting of a micro-opioid receptor agonist and an ORL1 receptor antagonist | Q44335548 | ||
| Effect of some peptidase inhibitors on exogenous and endogenous opioid actions in guinea-pig ileum | Q44338438 | ||
| Peripheral opioid receptors mediating antinociception in inflammation. Evidence for activation by enkephalin-like opioid peptides after cold water swim stress. | Q44338566 | ||
| Enkephalin antinociception in mice is mediated by delta 1- and delta 2-opioid receptors in the brain and spinal cord, respectively | Q44339126 | ||
| Opioid actions at mu and delta receptors in the rat dentate gyrus in vitro | Q44340321 | ||
| Peripheral non-opioid analgesic effects of kyotorphin in mice. | Q44347555 | ||
| Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice | Q44349438 | ||
| Transport of opioid peptides into the central nervous system. | Q44350552 | ||
| Intrathecal administration of p-hydroxymercuribenzoate or phosphoramidon/bestatin-combined induces antinociceptive effects through different opioid mechanisms | Q44350762 | ||
| The μ rather than the δ subtype of opioid receptors appears to be involved in enkephalin-induced analgesia | Q44351395 | ||
| The proenkephalin A-processing product peptide E, which encompasses two enkephalin sequences, has a much lower opioid activity than beta-endorphin | Q44352737 | ||
| Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study | Q44541822 | ||
| Analgesic effects of intra-nasal enkephalins | Q44646541 | ||
| Chemical modification of the monkey brain cytosolic aminopeptidase that cleaves enkephalin to its constituent amino acids. Evidence for essential tyrosine residue (residues) | Q44870663 | ||
| Occurrence of substance P(1-7) in the metabolism of substance P and its antinociceptive activity at the mouse spinal cord level. | Q44899853 | ||
| Metabolism and absorption enhancement of methionine enkephalin in human nasal epithelium | Q44912500 | ||
| Development of a new analgesic based on metabolism of endomorphin, an endogenous opioid peptide | Q45009305 | ||
| Inhibition of human plasma leucine5-enkephalin aminopeptidase hydrolysis by various endogenous peptides and a select number of clinically used drugs | Q45150222 | ||
| Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position. | Q45180464 | ||
| Protease inhibition increases the analgesic potency of peptide E. | Q46814924 | ||
| An Enkephalin-Degrading Aminopeptidase from Rat Brain Catalyzes the Hydrolysis of a Neuropeptide, Kyotorphin (L-Tyr-L-Arg) | Q46827139 | ||
| Protection against dynorphin-(1-8) hydrolysis in membrane preparations by the combination of amastatin, captopril and phosphoramidon | Q47723441 | ||
| Enkephalin-processing oligopeptidases in cobra venom: inhibition by thiorphan and bestatin reveals co-operative actions | Q47876497 | ||
| Penetration of dynorphin 1-13 across the blood-brain barrier | Q47930872 | ||
| 2S,3R 3-amino-2-hydroxy-4-phenylbutanoic acid derivatives, enkephalinase inhibitors, augment met5-enkephalin-induced antinociception | Q48106872 | ||
| Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin n. | Q48124598 | ||
| Engineering an endomorphin-2 gene for use in neuropathic pain therapy | Q48224100 | ||
| Electroacupuncture and morphine analgesia potentiated by bestatin and thiorphan administered to the nucleus accumbens of the rabbit | Q48310166 | ||
| Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies | Q48374935 | ||
| Dipeptidase activities in rat brain synaptosomes can be distinguished on the basis of inhibition by bestatin and amastatin: identification of a kyotorphin (Tyr-Arg)-degrading enzyme | Q48446518 | ||
| Kappa-binding and degradation of [3H]dynorphin A (1-8) and [3H]dynorphin A (1-9) in suspensions of guinea pig brain membranes | Q48451544 | ||
| Degradation of kyotorphin by a purified membrane-bound-aminopeptidase from monkey brain: potentiation of kyotorphin-induced analgesia by a highly effective inhibitor, bestatin | Q48488110 | ||
| How is kyotorphin (Tyr-Arg) generated in the brain? | Q48523895 | ||
| Sites of analgesic actions of kyotorphin and D-kyotorphin in the central nervous system of rats | Q48523958 | ||
| P304 | page(s) | 50 | |
| P577 | publication date | 2010-06-28 | |
| P1433 | published in | Frontiers in Neuroscience | Q2177807 |
| P1476 | title | The Analgesic Activity of Bestatin as a Potent APN Inhibitor | |
| P478 | volume | 4 |
| Q89553605 | COMT gene variants and β-endorphin levels contribute to ethnic differences in experimental pain sensitivity |
| Q82066518 | Immunocytochemistry for bestatin and its application to drug accumulation studies in rat intestine and kidney |
| Q41833735 | Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells |
| Q43240833 | The pro-inflammatory cytokine 14-3-3ε is a ligand of CD13 in cartilage |
Search more.